Anlon Healthcare Q4 FY26: ₹55 Cr Sales, But Cash Flow Turned Negative Again

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Anlon Healthcare’s fourth quarter of FY26 carries a quiet tension: revenues hit ₹55.42 crore (up 13.3% year-over-year), but operating profit fell to ₹13.91 crore from ₹17.19 crore in Q4 FY25. Full-year FY26 saw strong topline momentum at ₹176.5 crore (47% TTM growth), yet operating cash flow went deeper into deficit at ₹46.36 crore for the year—worse than FY25’s ₹22.55 crore outflow.

The company trades at 28.6x its trailing EPS of ₹0.52, around where peers like Lupin sit, but sits atop a debt-to-equity ratio of 0.22, a relatively clean sheet. The inventory pile surged to ₹75.59 crore (from ₹50.26 crore) and debtor days remain sticky at 215. One wisdom line: growth that ignores working capital dynamics rarely stays cheap for long.

Market cap is ₹794 crore. The company made three acquisitions in FY26 (Apiqo, Bizotic, Remember India). What changes when capacity scales but cash drains faster?

2. Introduction

Anlon Healthcare trades on NSE as AHCL and BSE as 544497. Incorporated in 2013, the Rajkot-based chemical manufacturer went public in September 2025, raising ₹121 crore in fresh issue. It makes pharmaceutical intermediates and active pharmaceutical ingredients (APIs)—the raw materials that drug makers use—and recently expanded into custom manufacturing for innovators.

The company operates out of Gujarat with installed capacity of 400 MTPA at the main plant and has acquired two subsidiaries (Apiqo and Bizotic) that bring another 1,000+ MTPA to the consolidated platform. Three acquisitions in one financial year is notable, though integration complexity and working capital strain are now real headwinds.

The 52.68% promoter holding (Punitkumar Rasadia, 34.98%; Meet Atulkumar Vachhani, 17.70%) is stable. Institutional ownership (DIIs) crept to 4.6% by year-end. The public holds 42.4%. Dividend payout is zero, and has been across all years in the data sheet.

3. Business Model: WTF Do They Even Do?

Anlon makes three things. First, pharmaceutical intermediates: high-purity chemicals used as starting blocks in the synthesis of APIs. Example: ketonitrile, a key starting material for ketoprofen.

Second, active pharmaceutical ingredients themselves. The company has 65 commercialized products and another 77 in the development pipeline (pilot and lab stage). Flagship APIs include loxoprofen sodium dihydrate, ketoprofen, and dexketoprofen trometamol—all non-steroidal anti-inflammatories (NSAIDs) used to treat pain, inflammation, and osteoarthritis. The company claims to be “among the few Indian manufacturers” of some of these.

Third, it’s lately offering custom manufacturing (CDMO) services—taking a customer’s molecule and scaling it from lab to commercial batches. The company is working on three molecules for two global innovators, with validation batches done and commercial supply expected by Q3/Q4 of FY27.

By revenue segment in FY26: pharmaceutical intermediates made up 71.2% of sales, APIs 26.4%, nutraceuticals 1.9%, and others 0.5%. The mix has shifted steadily; in FY25, APIs were 58% and intermediates were 36%. This suggests the company is moving down the value chain into intermediates—lower-priced, higher-volume stuff.

Geographically, FY25 was domestic-heavy: 96.76% of sales from India, 3.24% from exports. The business is concentrated among a tight set of customers; top 10 accounted for about 75-78% of revenue. Top-5 customer concentration was 28-29% in both FY26 and Q4. That’s ordinary for B2B pharma.

4. Financials Overview

Figures are consolidated, in ₹ crore.

For full-year FY26: Revenue of ₹176.5 crore (+46.7% YoY from FY25’s ₹120.29 crore). Operating profit ₹46 crore (26.1% OPM), up from FY25’s ₹33 crore. Reported PAT ₹27.81 crore (+35.5% YoY from FY25’s ₹20.52 crore). Full-year EPS was ₹0.52 per share (based on average shares outstanding). The ETM EPS is ₹0.52.

Q4 margin compression: OPM fell to 25.1% from 35.1% in Q4 FY25. PAT margin dropped from 34% to 21.75%. The company’s concall disclosed raw-material cost spikes (solvent/catalyst prices hitting all-time highs) and a lag in passing prices through to customers. By the start of FY27, management expected margin recovery, but the Q4 earnings show the drag was real.

Working capital mess: Cash conversion cycle widened to 332 days at year-end from 261 days in FY25. Debtor days hit 215 (invoice to cash), inventory days stayed around 245 (a spike from the acquired subsidiaries Apiqo and Bizotic, which came in early FY26). The company stated in the concall that it will enforce a 120-day credit cap going forward and expects FY27 operating cash flow to turn positive—a claim we’ll watch.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.